Navigation Links
Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Omniscan
Date:3/5/2008

GREAT NECK, N.Y., March 5 /PRNewswire/ -- Parker Waichman Alonso LLP announces that it has filed suit on behalf of a man diagnosed with Nephrogenic Systemic Fibrosis (NSF) after receiving two injections of Omniscan, a gadolinium contrast dye manufactured by General Electric Company, its subsidiaries and Novation LLC. NSF is a debilitating, often fatal disease that robs patients of their mobility. NSF is a condition that affects patients with pre-existing kidney disease who have been exposed to gadolinium contrast dyes such as Omniscan. Symptoms of NSF include thickening and hardening of the skin, joint problems, muscle weakness and eye discoloration. The lawsuit was filed in the US District Court for the Eastern District of Pennsylvania (Docket Number: 2:08-cv-1060)

Zbigniew Marcinczyk, a resident of Philadelphia and a patient with pre-existing kidney disease, received two injections of gadolinium contrast dye in September and December 2005. Representatives from Holy Redeemer Hospital and the University of Pennsylvania Hospital in Philadelphia have confirmed that the gadolinium contrast dye administered to Marcinczyk was Omniscan. Shortly after the administration of Omniscan, Marcinczyk developed and continues to suffer from the severe, debilitating and progressive fibrotic changes associated with NSF. This has permanently disabled, disfigured and severely impaired the plaintiff.

The lawsuit alleges that the chemical make-up of Omniscan makes it more likely that gadolinium will become free within the bodies of recipients, thereby making it more likely that kidney patients will develop NSF. The lawsuit further alleges that Omniscan is defective, and that the defendants failed to adequately test Omniscan and failed to warn patients about its potential to cause NSF. In September 2007, the Food & Drug Administration (FDA) asked the manufacturers of gadolinium contrast dyes to add a black box warning to the product labels about its association with NSF. The FDA also warned that patients with kidney disease should avoid gadolinium contrast agents. NSF is a devastating condition characterized by high blood pressure, burning, itching, swelling and hardening of the skin. Other symptoms include red or dark patches on the skin; pain deep in the hip bones or ribs and muscle weakness. NSF can progress to the point of causing severe stiffness in joints, and it can lead to death. There is currently no cure for NSF.

On February 29, the U.S. Judicial Panel on Multidistrict Litigation designated the U.S. District Court for the Northern District of Ohio as the venue for the many lawsuits that have been filed, and those that will be filed in federal district court, against the makers of gadolinium contrast dyes. An estimated 68 cases have been filed in more than a dozen different federal districts against gadolinium contrast dye manufacturers, including General Electric Company. The panel indicated that the Northern District Of Ohio provides a relatively central forum for the centralization of this nationwide litigation.

If you or a loved one has developed NSF after being administered a gadolinium contrast dye, please contact our office by visiting http://www.yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

About Parker Waichman Alonso LLP

Parker Waichman Alonso LLP is a leading products liability and personal injury law firm that represents plaintiffs nationwide. The firm has offices in New York and New Jersey. Parker Waichman Alonso LLP has assisted thousands of clients in receiving fair compensation for injuries resulting from defective products, tainted foods, medications and medical devices.

CONTACT: Parker Waichman Alonso LLP

Fred R. Rosenthal, Managing Attorney

(800) LAW-INFO

(800) 529-4636

info@yourlawyer.com

http://www.yourlawyer.com


'/>"/>
SOURCE Parker Waichman Alonso LLP
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. National Spokeswoman Eva Longoria Parker to Accept $200,000 Donation From AT&T to Benefit PADRES Contra El Cancer
2. Parker Waichman Alonso LLP, Becnel Law Firm, LLC, Douglas & London P.C., Levin
3. Parker Waichman Alonso LLP, Along with Smith & Nevares, Salas & Co. and Becnel
4. Watson Files Application for Generic SEASONIQUE(R)
5. Conseco Files to Formally Extend Due Date for Annual Report on Form 10-K to March 17 and Reschedules Earnings Release and Investor Call
6. RealSelf.com Denies Lifestyle Lifts Trademark Claims and Files Countersuit
7. Novo Nordisk Files Annual Report with the SEC
8. PLC Systems Files IDE Supplement to Begin Pivotal Study of RenalGuard(TM) and Provides Update on Planned Development Timeline
9. Digital Healthcare Files to Enjoin Two State of Ohio Departments; Charges Bid-Steering and Breach of Agreement in Program to Control Medicaid Overpayment of Insurance Claims
10. Aircraft Medical Files Counter Action Against Verathon
11. MDS Inc. Files Restated 2007 Quarterly Reports Under US GAAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... prominently feature 150+ Hospital and Health System Executive Speakers including: , , ... President of the United States of America: George W. Bush , Boxing Legend, ... Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... help improve all aspects of people’s health and nutrition, announced its product Leyzene ... , Natural Subsistence develops nutritional supplements that help people improve all aspects ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality Assurance and Utilization ... ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. , It is ... the association, but also to the Health Care Quality and Patient Safety movements. Diplomates ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 — ... the new EU MDR language change the way manufacturers approach CERs? , ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Beyond and Back”: a true-life ... is the creation of published author Bonetta Rose, a wife, mother and grandmother committed ... Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events in the ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... ReNeuron reported in December 2016 positive Phase II trial ... not meeting the three-month time frame of a two-point improvement ... (ARAT). As a result, the company has confirmed that it ... Beyond CTX, we expect safety and efficacy data from its ... from its critical limb ischaemia (CLI) trial. Our rNPV has ...
(Date:3/23/2017)... , Mar 23, 2017 The Board ... to the Annual General Meeting, which is to take place on ... 2 in Lund, Sweden . ... Please see the attached notification, which ... Inrikes Tidningar. NeuroVive Pharmaceutical AB (Publ) The Board Of ...
(Date:3/22/2017)... Corp. (NASDAQ: DRIO), a leading global digital health ... today reported financial and operational results for the ... 2016. 2016 Highlights ... to the full year 2015  ... Direct-to-consumer model launched in U.S. ...
Breaking Medicine Technology: